德曲妥珠单抗治疗转移性非小细胞肺癌(DESTINY-Lung01):HER2过表达队列的单臂2期试验主要结果
DESTINY-Lung01是一项多中心、开放标签、2期研究,评估德曲妥珠单抗在HER2过表达或HER2(ERBB2)突变不可切除或转移性非小细胞肺癌(NSCLC)中的抗肿瘤活性和安全性。本文报告队列1和1A的主要分析,旨在评估德曲妥珠单抗5.4 mg/kg和6.4 mg/kg在HER2过表达NSCLC患者中的活性和安全性。
要点
- 队列1(6.4 mg/kg)确认的客观缓解率为26.5%(95% CI 15.0-41.1;49例中13例,均为部分缓解)。
- 队列1A(5.4 mg/kg)确认的客观缓解率为34.1%(95% CI 20.1-50.6;41例中14例,其中2例完全缓解、12例部分缓解)。
- 作者认为德曲妥珠单抗可能填补HER2过表达NSCLC的巨大未满足需求,支持进一步研究。
核心结论
- 鉴于该患者群体现有治疗方案的抗肿瘤活性较低,德曲妥珠单抗可能具有填补HER2过表达NSCLC巨大未满足需求的潜力。
- 研究结果支持在HER2过表达NSCLC患者中进一步研究德曲妥珠单抗。
研究设计与样本
- DESTINY-Lung01是一项多中心、开放标签、2期研究,评估德曲妥珠单抗在HER2过表达或HER2(ERBB2)突变不可切除或转移性NSCLC患者中的抗肿瘤活性和安全性。
- 患者年龄18岁及以上,患不可切除或转移性(或两者兼有)非鳞状NSCLC,在接受标准治疗后复发或难治,或无标准治疗可用,HER2免疫组化评分为3+或2+(无已知HER2突变),美国东部肿瘤协作组体能状态评分为0或1。
- 患者在法国、日本、荷兰、西班牙和美国的20家专科医院入组;患者序贯分配至队列1(德曲妥珠单抗6.4 mg/kg)和队列1A(德曲妥珠单抗5.4 mg/kg),均每3周静脉给药一次。
- 主要终点为独立中心审查确认的客观缓解率,在完整分析集中评估,完整分析集包括所有签署知情同意书并入组的患者;安全性在所有接受至少一剂德曲妥珠单抗的入组患者中评估。
- 2018年8月27日至2020年1月28日,队列1入组49例患者(中位年龄63.0岁[IQR 58.0-68.0],30例[61%]男性,19例[39%]女性,31例[63%]白人);2020年6月16日至12月9日,队列1A入组41例患者(中位年龄62.0岁[IQR 56.0-66.0],22例[54%]男性,19例[46%]女性,31例[76%]白人)。
主要发现
- 截至数据截止日(2021年12月3日),队列1中位治疗持续时间为4.1个月(IQR 1.4-7.1),队列1A为5.5个月(IQR 1.4-8.7);队列1中位随访时间为12.0个月(IQR 5.4-22.4),队列1A为10.6个月(IQR 4.5-13.5)。
- 独立中心审查确认的客观缓解率在队列1为26.5%(95% CI 15.0-41.1;49例中13例,均为部分缓解),在队列1A为34.1%(95% CI 20.1-50.6;41例中14例,其中2例完全缓解、12例部分缓解)。
- 最常见的3级或以上治疗中出现的不良事件为中性粒细胞减少(队列1:49例中12例[24%];队列1A:无)、肺炎(分别为6例[12%]和2例[5%])、乏力(分别为6例[12%]和3例[7%])和疾病进展(分别为6例[12%]和4例[10%])。
- 药物相关3级或以上治疗中出现的不良事件在队列1的41例患者中发生26例(53%),在队列1A的49例患者中发生9例(22%);药物相关严重不良事件分别为10例(20%)和3例(7%)。
- 治疗中出现的不良事件导致的死亡在队列1发生10例(20%)(疾病进展6例[12%],支气管痉挛、脑积水、呼吸衰竭和肺炎各1例[2%]),在队列1A发生7例(17%)(疾病进展4例[10%],呼吸困难、恶性肿瘤和脓毒症各1例[2%]);研究者判定1例死亡(队列1中的肺炎)由研究治疗导致。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: DESTINY-Lung01 is a multicentre, open-label, phase 2 study evaluating the antitumour activity and safety of trastuzumab deruxtecan, a HER2-directed antibody-drug conjugate, in patients with HER2-overexpressing or HER2 (ERBB2)-mutant unresectable or metastatic non-small-cell lung cancer (NSCLC). The results of the HER2-mutant cohort (cohort 2) have been reported elsewhere. Herein, we report the primary analysis of cohorts 1 and 1A, which aimed to evaluate the activity and safety of trastuzumab deruxtecan 5·4 mg/kg and 6·4 mg/kg in patients with HER2-overexpressing NSCLC. METHODS: Patients aged 18 years or older with unresectable or metastatic (or both unresectable and metastatic) non-squamous NSCLC who had relapsed following or were refractory to standard treatment or for whom no standard treatment was available, with an HER2 immunohistochemistry score of 3+ or 2+ (without known HER2 mutations) and an Eastern Cooperative Oncology Group performance status score of 0 or 1, were enrolled at 20 specialist hospitals in France, Japan, the Netherlands, Spain, and the USA. Patients were assigned to cohorts sequentially, first to cohort 1, to receive trastuzumab deruxtecan 6·4 mg/kg (cohort 1), then to cohort 1A, to receive trastuzumab deruxtecan 5·4 mg/kg, both administered intravenously once every 3 weeks. The primary endpoint was confirmed objective response rate by independent central review and was assessed in the full analysis set, which included all patients who signed an informed consent form and were enrolled in the study. Safety was assessed in all enrolled patients who received at least one dose of trastuzumab deruxtecan. This trial is registered with ClinicalTrials.gov, NCT03505710, and is ongoing (closed to recruitment). FINDINGS: Between Aug 27, 2018, and Jan 28, 2020, 49 patients were enrolled in cohort 1 (median age 63·0 years [IQR 58·0-68·0], 30 [61%] male, 19 [39%] female, and 31 [63%] White), and from June 16 to Dec 9, 2020, 41 patients were enrolled in cohort 1A (median age 62·0 years [IQR 56·0-66·0], 22 [54%] male, 19 [46%] female, and 31 [76%] White). As of data cutoff (Dec 3, 2021), the median treatment duration was 4·1 months (IQR 1·4-7·1) in cohort 1 and 5·5 months (1·4-8·7) in cohort 1A, and median follow-up was 12·0 months (5·4-22·4) in cohort 1 and 10·6 months (4·5-13·5) in cohort 1A. Confirmed objective response rate by independent central review was 26·5% (95% CI 15·0-41·1; 13 of 49, all partial responses) in cohort 1 and 34·1% (20·1-50·6; 14 of 41; two complete responses and 12 partial responses) in cohort 1A. The most common treatment-emergent adverse events of grade 3 or worse were neutropenia (12 [24%] of 49 in cohort 1, none in cohort 1A), pneumonia (six [12%] and two [5%], respectively), fatigue (six [12%] and three [7%], respectively), and disease progression (six [12%] and four [10%], respectively). Drug-related treatment-emergent adverse events of grade 3 or worse occurred in 26 (53%) of 41 patients in cohort 1 and nine (22%) of 49 patients in cohort 1A. Drug-related serious adverse events were reported in ten (20%) patients and three (7%) patients, respectively. Deaths due to treatment-emergent adverse events occurred in ten (20%) patients in cohort 1 (disease progression in six (12%) patients and bronchospasm, hydrocephalus, respiratory failure, and pneumonitis in one [2%] patient each), and in seven (17%) patients in cohort 1A (due to disease progression in four (10%) patients and dyspnoea, malignant neoplasm, and sepsis in one (2%) patient each). One death due to a treatment-emergent adverse event was determined to be due to study treatment by the investigator, which was in cohort 1 (pneumonitis). Independent adjudication of interstitial lung disease or pneumonitis found that drug-related interstitial lung disease or pneumonitis occurred in ten (20%) patients in cohort 1 (two [4%] grade 1, five [10%] grade 2, and three [6%] grade 5) and two (5%) patients in cohort 1A (one [2%] grade 2 and one [2%] grade 5). An additional patient in cohort 1A had grade 4 pneumonitis after the data cutoff, which was subsequently adjudicated as drug-related grade 5 interstitial lung disease or pneumonitis. INTERPRETATION: Given the low antitumour activity of existing treatment options in this patient population, trastuzumab deruxtecan might have the potential to fill a large unmet need in HER2-overexpressing NSCLC. Our findings support further investigation of trastuzumab deruxtecan in patients with HER2-overexpressing NSCLC. FUNDING: Daiichi Sankyo and AstraZeneca.
引用
- Smit EF, Felip E, Uprety D, et al. Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial. Lancet Oncol. 2024. PMID: 38547891. doi:10.1016/S1470-2045(24)00064-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。